Biotechnology is a top-notch field of study that emerged into the scientific world as a result of revolutions in Biology, Chemistry, Informatics, and Engineering. It is considered to be an applied branch of Biology. Biotechnology helps out this old and respectable field of science keep up with the pace of time and remain competitive in the contemporary world. With a Master in Biotechnology, students will study the use of living organisms and bioprocesses in technology, engineering, medicine, agriculture and results in all kinds of bioproducts, from genetically modified food to serious cutting-edge devices used to carry out gene therapy. Students in Master in Biotechnology programs may also explore bioinformatics, which is the application of statistics and computer science to the field of molecular biology. Bioinformatics is extremely important for contemporary biological and molecular researches because the data amount there grows by geometric progression and it is necessary to have adequate technology to process it. Bioinformatic methods are widely used for mapping and analyzing DNA and protein samples, as well as for the study of genetics and molecular modeling. Biotechnology and Bioinformatics do a great favour to traditional fields of study, refreshing them with new methods of research, which allows their … Continue reading →

By Elizabeth Johnson Leading pharmaceutical and biotechnology companies chose INTERPHEX 2017 to launch their newest products, with 20 companies debuting new technology at the pharmaceutical and biotechnology industry trade show held March 21-23 at the Jacob K. Javits Convention Center in New York City. In its 38th year, INTERPHEX offered attendees a mix of content including more than 104 conference education sessions, INTERPHEX Live discussions, hundreds of exhibits and product launches. The show experienced attendee growth, compared with 2016, and attributes much of that to its robust program. INTERPHEX offers its customers the opportunity to bring their entire teams and engage in education for everyone, said Melissa Ashley, senior vice president of INTERPHEX. She continued, Attendance is free to those who register ahead to support the industry and allow companies full teams to experience all that is happening in the industry. Having grown and evolved from a regional to a national and international event, INTERPHEX selected New York as its home because the city is a gateway that allows people to come from abroad and because there are a lot of customers in the tri-state area. INTERPHEX is reflective of the industry advancing to the future, with organizers working to … Continue reading →

March 31, 2017 9:38am NASDAQ:BBC From Zacks: After being stressed by the twin attacks of higher drug pricing and increased regulatory scrutiny, the biotech sector has made a strong comeback in the first quarter of 2017. In fact, BioShares Biotechnology Clinical Trials ETF (BBC Free Report) tops the list of the best performing ETFs of the quarter, with impressive returns of about 27.4%. BBC carries a Zacks ETF Rank of 3 or Hold rating with a High risk outlook. The surge in the fund was largely driven by cheap valuation, robust earnings results and a slew of positive actions taken by the President. In particular, Trump promised to reduce federal regulations by 7580% and streamline the Food & Drug Administration (FDA) approval process. This would make it easier for biotech companies to bring new products to the market. Trumps proposed tax reforms and cash repatriation policy are also supporting the rally (read: Top ETF Stories of Q1 from Wall Street). Apart from these, encouraging industry trends including the possibility of increased M&A activity, an accelerated pace of innovation, promising drug launches, growing importance of biosimilars, cost-cutting efforts, an aging population, expanding insurance coverage, the growing middle class, an insatiable demand … Continue reading →

Shares of Cellect Biotechnology Ltd. (APOP) are up more than 44% over the last 5 trading days. With its shares currently traded on both the NASDAQ and Tel Aviv Stock Exchange, Cellect is the company behind ApoGraft, a breakthrough technology for the isolation of stem cells from any given tissue. Cellect's ApoGraft technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks, such as Graft versus Host Disease. Graft versus Host Disease, a condition in which the transplanted immune cells attack the recipient's cells, is a common complication associated with *allogeneic stem cell transplantation. (*Allogeneic stem cell transplantation involves transferring the stem cells to the recipient from a genetically matched relative or other donor). The positive results from a clinical trial of ApoGraft that involved 104 healthy donors of blood stem cells reported in February of this year demonstrated that Cellect's ApoGraft is a safe, robust and reproducible process for clinical use. According to the company, the use of the ApoGraft to process human stem cells for bone marrow transplantation resulted in a significant increase in the death of mature immune … Continue reading →